when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog
drugs
Sivextro

drug · small molecule

tedizolid phosphate

Marketedupdated 3mo ago

by $MRK Merck & Co., Inc.🔗 ChEMBL

Approved

community read0 votes

🐶 often sniffed alongside

top 3

tagApproval112 co-mentions · 28 sources
drugSIVEXTRO112 co-mentions · 28 sources
tagSmall Molecule32 co-mentions · 16 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 6 investigational indications.

targets

Bacterial 70S ribosome

all catalysts(28)

approval · 28

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

SIVEXTRO (TEDIZOLID PHOSPHATE) — FDA approval

tedizolid phosphate

view all 28 catalysts →

Trials studying tedizolid phosphate

phase3A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)completedn=100
phase1A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)completedn=47
phase1A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)completedn=36
phase1A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)completedn=18

Patent cliff

source: FDA Orange Book

first barrier falls

Feb 23, 2028

~1.5 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (14)

Dec 31, 2030compositionUS 84263894.4y
Dec 31, 2030compositionUS 84263894.4y
Feb 3, 2030formulationUS 100659473.5y
Feb 3, 2030formulationUS 100659473.5y
Feb 3, 2030compositionUS 104428293.5y
Feb 3, 2030compositionUS 104428293.5y
Feb 3, 2030compositionUS 96242503.5y
Feb 3, 2030compositionUS 96242503.5y
Feb 3, 2030formulationUS 99884063.5y
Feb 3, 2030formulationUS 99884063.5y
Jun 20, 2028compositionUS 78163791.8y
Jun 20, 2028compositionUS 78163791.8y
Feb 23, 2028compositionUS 84206761.5y
Feb 23, 2028compositionUS 84206761.5y

FDA exclusivities (2)

Apr 4, 2028NPPNew Product (3y)1.6y
Apr 4, 2028NPPNew Product (3y)1.6y

News(0)

no news has mentioned this drug yet

brand

Sivextro

trade names

Sivextro

generic

tedizolid phosphate

MOA

Bacterial 70S ribosome inhibitor

indication

Skin And Skin Structure Infections (SSSI) Caused By Bacteria

phase

marketed

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 5m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?